We suggest using renin–angiotensin system inhibitors (RASi) (angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB)) as a first line of antihypertensive therapy in people with high BP and CKD [expert opinion], and recommend ACEi or ARB in those with increased albuminuria (A2 (2C) and A3 (1B)). Here, ACE is linked to chronic kidney disease.